LivaNova (LIVN) Q4 2025 earnings review
Strong 2025 Finish Obscured by Decelerating 2026 Outlook
LivaNova capped off a strong 2025 with 9.5% organic revenue growth in Q4 and solid margin expansion, effectively closing the books on the SNIA litigation overhang that dominated the year's GAAP metrics. However, guidance for 2026 signals a meaningful deceleration. Revenue growth is projected to slow to 6.0-7.0%, and adjusted free cash flow guidance implies a year-over-year decline. The brightest spot moving forward is a massive 48% CMS reimbursement bump for VNS Therapy, which provides a structural tailwind for the Neuromodulation segment.
🐂 Bull Case
Effective January 1, 2026, hospital outpatient payments for VNS Therapy DRE procedures rise by ~48%. This massive structural shift severely reduces a known barrier to procedure penetration and drastically improves hospital economics.
Full-year adjusted operating margin expanded to 20.6% from 19.1% the prior year, proving management's ability to drive fixed cost leverage and optimize the P&L even while investing in the Obstructive Sleep Apnea (OSA) pipeline.
🐻 Bear Case
After a year of double-digit expansion (10.7% organic growth in FY25), top-line growth is guiding down to 6.0-7.0% for FY26. The Essenz Heart-Lung Machine upgrade cycle may be reaching a maturation phase.
Despite guided top-line and EPS growth, FY26 Adjusted Free Cash Flow is forecasted to drop to a midpoint of $170M from FY25's $183.3M, raising questions about capital intensity and working capital needs.
⚖️ Verdict: ⚪
Neutral. The operational execution in 2025 was excellent, and the VNS reimbursement win is a major 2026 catalyst. However, slowing top-line growth and shrinking free cash flow guidance limit the upside case until the new OSA division proves it can become a primary growth engine.
Key Themes
Massive VNS Therapy Reimbursement Win
Accelerating. The U.S. Centers for Medicare & Medicaid Services (CMS) significantly increased provider reimbursement for VNS Therapy for Drug-Resistant Epilepsy (DRE). Rising by approximately 48% for new patient implants and 47% for end-of-service procedures vs 2025 rates, this structurally changes the economics for hospitals and serves as a primary adoption driver for 2026.
Cardiopulmonary Market Share and Essenz Upgrades
Stable. The Cardiopulmonary segment continued its reign as the workhorse, driven by sustained demand for oxygenator consumables and the ongoing global placement of the Essenz Perfusion System. While the initial surge of Essenz upgrades might be stabilizing, consistent consumable volume continues to buoy segment profitability.
Narrative Contradiction: Cash Flow Trajectory Reversing
Reversing. Management touted 'robust cash generation' in their earnings release commentary. However, looking at the data, this narrative contradicts their own FY26 outlook. Adjusted Free Cash Flow is guided to $160-$180M (midpoint $170M). This represents an outright decline from FY25's $183.3M, signaling higher capital expenditures or working capital absorption ahead.
Top-Line Growth Decelerating
Decelerating. LivaNova posted 10.7% organic growth in FY25, but the FY26 constant-currency revenue guidance of 6.0-7.0% marks a pronounced slowdown. Management must navigate tougher year-over-year comparables, putting pressure on the Neuromodulation segment to pick up the slack as Cardiopulmonary growth normalizes.
Digital Health and OSA Infrastructure Scaling
The company received FDA approval for its cloud-based digital health platform, establishing the digital foundation for its DRE patient journey. Concurrently, the appointment of Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea (OSA) signals a shift from clinical trials to active commercial ramp-up.
Macro Backdrop: Foreign Exchange Flips to Tailwind
Reversing. Unlike the first half of 2025 where foreign exchange and tariffs were cited as headwinds, management anticipates a ~1.0% FX tailwind for FY26 based on current exchange rates, offering a slight cushion to the decelerating organic growth profile.
Other KPIs
Accelerating. Adjusted operating margin expanded 150 basis points from 19.1% in FY24 to 20.6% in FY25. This proves management's ability to drive operating leverage despite inflation and supply chain bottlenecks.
Reversing. Due to the massive $365.6M SNIA environmental liability recorded earlier in the year, full-year GAAP results plunged into the red. While this is treated as a non-GAAP adjustment, it represents a real future cash obligation that limits capital allocation flexibility.
Accelerating. The segment accelerated from 6.9% growth in Q3 to 11.0% in Q4. It indicates strong commercial execution heading into 2026, perfectly timing the upcoming CMS reimbursement bump.
Guidance
Decelerating. A clear step-down from the 9.7% constant currency growth (10.7% organic) achieved in FY25. Indicates the base business is normalizing after catching up on pent-up capital equipment demand.
Decelerating. The midpoint of $4.20 implies a 7.7% year-over-year increase from FY25's $3.90. This is slower than the 15.4% earnings growth achieved from FY24 to FY25.
Reversing. Down from $183.3 million in FY25. This contraction in free cash flow, despite projected EPS growth, requires monitoring. It likely stems from necessary CapEx to build out the OSA commercial infrastructure or working capital absorption.
Key Questions
Bridging the Free Cash Flow Decline
What are the specific drivers behind the expected decline in Adjusted Free Cash Flow for 2026 ($170M midpoint) despite a growing bottom line? Is this primarily driven by CapEx for the OSA launch, or are there anticipated working capital headwinds?
CMS Reimbursement Economics
With the 48% increase in Medicare reimbursement for VNS Therapy, how much of this economic benefit will translate into realized pricing for LivaNova versus margin retention for the hospitals? What volume elasticity is built into the 2026 guidance?
OSA Commercial Ramp
Following the FDA approval of the digital health platform and the appointment of Lucile Blaise as Global Head of OSA, what is the precise commercialization timeline? Does the FY26 revenue guidance include any material contribution from sleep apnea product sales?